Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C

C Liddle1

  • 1Department of Clinical Pharmacology, Westmead Hospital, Sydney, Australia.

Anaesthesia and Intensive Care
|April 1, 1996
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) infection is primarily transmitted through intravenous drug use, with over 90% prevalence in this group. While treatments exist for mild cases, no vaccine or effective post-exposure prophylaxis is available.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B.

Alimentary pharmacology & therapeutics·2018
Same author

IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection.

Genes and immunity·2016
Same author

Cistromic and genetic evidence that the vitamin D receptor mediates susceptibility to latitude-dependent autoimmune diseases.

Genes and immunity·2016
Same author

Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.

Genes and immunity·2013
Same author

Prospective data collection of off-label use of rituximab in Australian public hospitals.

Internal medicine journal·2013
Same author

Voriconazole toxicity related to polymorphisms in CYP2C19.

Internal medicine journal·2011
Same journal

A brief history of colour in the operating theatre.

Anaesthesia and intensive care·2026
Same journal

Evaluating the completeness of perioperative outcome metrics in electronic medical records: Insights based on the proposed Perioperative Clinical Outcomes Registry framework.

Anaesthesia and intensive care·2026
Same journal

Large language model prompt engineering for medical education: A practical guide for the Australian and New Zealand College of Anaesthetists Final Examination.

Anaesthesia and intensive care·2026
Same journal

Nitrous oxide added at the end of sevoflurane anaesthesia hastens emergence and eliminates prolonged time to extubation (SEVONATE study): A randomised controlled trial.

Anaesthesia and intensive care·2026
Same journal

Complications related to arterial line catheters and monitoring reported to webAIRS, 2009-2023.

Anaesthesia and intensive care·2026
Same journal

A summary guide for detecting and reducing nitrous oxide infrastructure leaks in healthcare facilities.

Anaesthesia and intensive care·2026
See all related articles

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) identified in the late 1980s causes most non-A, non-B hepatitis.
  • Prevalence of anti-HCV antibodies is 0.3% in the general Australian population, exceeding 90% in intravenous drug users.
  • Key risk factors include intravenous drug use, tattoos, blood product exposure, occupational risks, and ethnicity.

Purpose of the Study:

  • To summarize the epidemiology, transmission, and current management of Hepatitis C virus infection.
  • To highlight the high prevalence in specific risk groups and the challenges in prevention and treatment.

Main Methods:

  • Review of existing literature on Hepatitis C virus epidemiology and clinical management.
  • Analysis of prevalence data in different population subsets.

Related Experiment Videos

  • Evaluation of current and potential therapeutic strategies.

    • Main Results:

    • HCV infection is predominantly linked to intravenous drug use.
    • Sexual and vertical transmission are uncommon.
    • Acute infections are often asymptomatic, with 50-80% progressing to chronic disease, and an estimated 20% developing cirrhosis.
    • Recombinant interferons show efficacy in mild to moderate liver disease but are less effective in cirrhosis.

    Conclusions:

    • HCV poses a significant public health challenge, particularly for intravenous drug users.
    • Current treatment options are limited, especially for advanced liver disease.
    • Lack of vaccine and effective post-exposure prophylaxis necessitates focus on prevention and early intervention.